77 related articles for article (PubMed ID: 33894495)
1. Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
Horiuchi K; Sato T; Kuno T; Takagi H; Hirsch FR; Powell CA; Fukunaga K
Lung Cancer; 2021 Jun; 156():59-67. PubMed ID: 33894495
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.
Sekikawa M; Murakami H; Morita M; Doshita K; Miura K; Kodama H; Morikawa N; Iida Y; Mamesaya N; Kobayashi H; Ko R; Wakuda K; Ono A; Kenmotsu H; Naito T; Chiba H; Takahashi T
Thorac Cancer; 2023 Dec; 14(35):3475-3482. PubMed ID: 37873674
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy advances in small-cell lung cancer.
Chan BA; Coward JI
J Thorac Dis; 2013 Oct; 5 Suppl 5(Suppl 5):S565-78. PubMed ID: 24163749
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer.
Nair BS; Bhanderi V; Jafri SH
Clin Med Insights Oncol; 2011; 5():223-34. PubMed ID: 21836818
[TBL] [Abstract][Full Text] [Related]
5. Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.
Ojemuyiwa M; Zeman K; Spira A; Oronsky B; Ray C; Trepel JB; Lee MJ; Onyiuke I; Brzezniak C
Clin Case Rep; 2018 Dec; 6(12):2478-2481. PubMed ID: 30564353
[TBL] [Abstract][Full Text] [Related]
6. Correction to: Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Oncologist; 2024 Jan; 29(1):e166. PubMed ID: 38000087
[No Abstract] [Full Text] [Related]
7. scIBD: a self-supervised iterative-optimizing model for boosting the detection of heterotypic doublets in single-cell chromatin accessibility data.
Zhang W; Jiang R; Chen S; Wang Y
Genome Biol; 2023 Oct; 24(1):225. PubMed ID: 37814314
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis-the META-L-BRAIN Study.
Teixeira Loiola de Alencar V; Guedes Camandaroba MP; Pirolli R; Fogassa CAZ; Cordeiro de Lima VC
J Thorac Oncol; 2021 Aug; 16(8):1379-1391. PubMed ID: 33964398
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.
Yoneshima Y; Morita S; Ando M; Nakamura A; Iwasawa S; Yoshioka H; Goto Y; Takeshita M; Harada T; Hirano K; Oguri T; Kondo M; Miura S; Hosomi Y; Kato T; Kubo T; Kishimoto J; Yamamoto N; Nakanishi Y; Okamoto I
J Thorac Oncol; 2021 Sep; 16(9):1523-1532. PubMed ID: 33915251
[TBL] [Abstract][Full Text] [Related]
11. Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition - A cohort study.
Daynes E; Gerlis C; Chaplin E; Gardiner N; Singh SJ
Chron Respir Dis; 2021; 18():14799731211015691. PubMed ID: 33957805
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
[TBL] [Abstract][Full Text] [Related]
13. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
See I; Su JR; Lale A; Woo EJ; Guh AY; Shimabukuro TT; Streiff MB; Rao AK; Wheeler AP; Beavers SF; Durbin AP; Edwards K; Miller E; Harrington TA; Mba-Jonas A; Nair N; Nguyen DT; Talaat KR; Urrutia VC; Walker SC; Creech CB; Clark TA; DeStefano F; Broder KR
JAMA; 2021 Jun; 325(24):2448-2456. PubMed ID: 33929487
[TBL] [Abstract][Full Text] [Related]
14. Protecting Olympic Participants from Covid-19 - The Urgent Need for a Risk-Management Approach.
Sparrow AK; Brosseau LM; Harrison RJ; Osterholm MT
N Engl J Med; 2021 Jul; 385(1):e2. PubMed ID: 34033274
[No Abstract] [Full Text] [Related]
15. Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis.
Lei H; Yang Y; Zhou W; Zhang M; Shen Y; Tao D; Wang L; Lei Q; Wang Y; Wu Y
Lung Cancer; 2021 Jul; 157():60-65. PubMed ID: 33985850
[TBL] [Abstract][Full Text] [Related]
16. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.
Pottegård A; Lund LC; Karlstad Ø; Dahl J; Andersen M; Hallas J; Lidegaard Ø; Tapia G; Gulseth HL; Ruiz PL; Watle SV; Mikkelsen AP; Pedersen L; Sørensen HT; Thomsen RW; Hviid A
BMJ; 2021 May; 373():n1114. PubMed ID: 33952445
[TBL] [Abstract][Full Text] [Related]
17. Shift work is associated with positive COVID-19 status in hospitalised patients.
Maidstone R; Anderson SG; Ray DW; Rutter MK; Durrington HJ; Blaikley JF
Thorax; 2021 Jun; 76(6):601-606. PubMed ID: 33903187
[TBL] [Abstract][Full Text] [Related]
18. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
[TBL] [Abstract][Full Text] [Related]
19. Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
Froesch P; Mark M; Rothschild SI; Li Q; Godar G; Rusterholz C; Oppliger Leibundgut E; Schmid S; Colombo I; Metaxas Y; König D; Sessa C; Gautschi O; Früh M;
Lung Cancer; 2021 Jun; 156():91-99. PubMed ID: 33933896
[TBL] [Abstract][Full Text] [Related]
20. Meta-Analysis Comparing Same-Sitting and Staged Percutaneous Coronary Intervention of Non-Culprit Artery for ST-Elevation Myocardial Infarction with Multivessel Coronary Disease.
Ueyama H; Kuno T; Yasumura K; Vengrenyuk Y; Takagi H; Barman N; Suleman J; Banning AS; Boxma-de Klerk BM; Smits PC; Kini A; Sharma SK
Am J Cardiol; 2021 Jul; 150():24-31. PubMed ID: 34011437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
